Drug Profile

Imapextide - MBX Biosciences

Alternative Names: MBX-1416

Latest Information Update: 26 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator MBX Biosciences
Class Antihypoglycaemics; Peptide hormones
Mechanism of Action Glucagon-like peptide-1 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Hypoglycaemia

Most Recent Events

26 Sep 2025 Phase-II clinical trials in Hypoglycaemia in USA (SC) (Prior to September 2025) (NCT07029412) (MBX Biosciences pipeline, September 2025)
07 Aug 2025 MBX Biosciences plans a phase IIa trial for Hypoglycaemia in the US, in the third quarter of 2025 (SC, Injection) (NCT07029412)
07 Jan 2025 Pharmacodynamic, pharmacokinetic and adverse event data from a phase I/II trial in Hypoglycemia was released by MBX Biosciences

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com